A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease.

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs VI 1121 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Nov 2012 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 08 Nov 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top